AC
ACET icon

AXQ Capital’s Adicet Bio ACET Stock Holding History

AXQ Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-810
Closed -$116K – 472
2022
Q4 		$116K Buy
+810
New +$202K 0.08% 298

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

AXQ Capital's ACET Position: Q1 2023 in Review

AXQ Capital sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 810 shares — an estimated $116K sold.

AXQ Capital first reported a position in ACET in Q4 2022 and held it in 1 quarter. The position peaked at $116K in Q4 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

  • AXQ Capital reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
  • AXQ Capital sold 810 Adicet Bio shares in Q1 2023, an estimated $116K.
  • AXQ Capital first reported a position in Adicet Bio in Q4 2022 and held it in 1 quarter.
  • AXQ Capital's Adicet Bio position peaked at $116K in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on AXQ Capital's 13F filing for Q1 2023, filed 10 May 2023.